Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

2.910 +0.130 (+4.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 922,613
Open 2.850
Bid (Size) 2.790 (1)
Ask (Size) 3.590 (4)
Prev. Close 2.780
Today's Range 2.720 - 2.940
52wk Range 2.255 - 5.340
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
From Savara Inc.
Via Business Wire

Performance

YTD
-5.2%
-5.2%
1 Month
+18.3%
+18.3%
3 Month
-5.5%
-5.5%
6 Month
-31.4%
-31.4%
1 Year
-39.9%
-39.9%

More News

Read More
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025
From Savara Inc.
Via Business Wire
Savara Announces U.S. Launch of the aPAP ClearPath™ Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Savara Announces Participation in the Leerink Global Healthcare Conference
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research
From Savara Inc.
Via Business Wire
Savara Announces Participation in Upcoming Healthcare Investor Conferences
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
From Savara Inc.
Via Business Wire
Savara Announces Participation in Upcoming Healthcare Conferences
From Savara Inc.
Via Business Wire
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
From Savara Inc.
Via Business Wire
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
From Savara Inc.
Via Business Wire
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
From Savara Inc.
Via Business Wire

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 2.910
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 03/28/25 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 331.93M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 332M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS